Latent Membrane Protein 1 as a Molecular Adjuvant for Single-Cycle Lentiviral Vaccines

DSpace/Manakin Repository

Latent Membrane Protein 1 as a Molecular Adjuvant for Single-Cycle Lentiviral Vaccines

Citable link to this page

. . . . . .

Title: Latent Membrane Protein 1 as a Molecular Adjuvant for Single-Cycle Lentiviral Vaccines
Author: Gupta, Sachin; Termini, James M; Niu, Liguo; Kanagavelu, Saravana K; Kornbluth, Richard S; Stone, Geoffrey W; Evans, David T.; Rahmberg, Andrew Richard

Note: Order does not necessarily reflect citation order of authors.

Citation: Gupta, Sachin, James M. Termini, Liguo Niu, Saravana K. Kanagavelu, Andrew R. Rahmberg, Richard S. Kornbluth, David T. Evans, and Geoffrey W. Stone. 2011. Latent Membrane Protein 1 as a molecular adjuvant for single-cycle lentiviral vaccines. Retrovirology 8:39.
Full Text & Related Files:
Abstract: Background Molecular adjuvants are a promising method to enhance virus-specific immune responses and protect against HIV-1 infection. Immune activation by ligands for receptors such as CD40 can induce dendritic cell activation and maturation. Here we explore the incorporation of two CD40 mimics, Epstein Barr Virus gene LMP1 or an LMP1-CD40 chimera, into a strain of SIV that was engineered to be limited to a single cycle of infection. Results Full length LMP1 or the chimeric protein LMP1-CD40 was cloned into the nef-locus of single-cycle SIV. Human and Macaque monocyte derived macrophages and DC were infected with these viruses. Infected cells were analyzed for activation surface markers by flow cytometry. Cells were also analyzed for secretion of pro-inflammatory cytokines IL-1β, IL-6, IL-8, IL-12p70 and TNF by cytometric bead array. Conclusions Overall, single-cycle SIV expressing LMP1 and LMP1-CD40 produced a broad and potent T\(_H\)1-biased immune response in human as well as rhesus macaque macrophages and DC when compared with control virus. Single-cycle SIV-LMP1 also enhanced antigen presentation by lentiviral vector vaccines, suggesting that LMP1-mediated immune activation may enhance lentiviral vector vaccines against HIV-1.
Published Version: doi://10.1186/1742-4690-8-39
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118346/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:5130450

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters